WoundReference improves clinical decisions
 Choose the role that best describes you
Snyder RJ, Shimozaki K, Tallis A, Kerzner M, Reyzelman A, Lintzeris D, Bell D, Rutan RL, Rosenblum B, et al.
Wounds : a compendium of clinical research and practice. Date of publication 2016 Mar 1;volume 28(3):70-7.
1. Wounds. 2016 Mar;28(3):70-7. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. Snyder RJ(1), Shimozaki K(2), Tallis A(3), Kerzner M(4), Reyzelman A(5), Lintzeris D(6), Bell D(7), Rutan RL(8), Rosenblum B(9). Author information: (1)Barry University Clinical Research, North Miami Beach, FL. (2)Pacific Wound Center, Stockton, CA; (3)Associated Foot and Ankle Specialists, Phoenix, AZ. (4)Duke University Medical Center, Durham, NC. (5)Center for Clinical Research, San Francisco, CA. (6)Wayne Memorial Wound Healing and Hyperbaric Center, Goldsboro, NC. (7)First Coast Cardiovascular Institute, Jacksonville, FL. (8)Derma Sciences Inc, Princeton, NJ. (9)Beth Israel Deaconess Hospital, Plymouth, MA. Delayed closure of foot ulcers is a primary factor leading to lower extremity amputation in patients with diabetes, creating great demand for products or therapies to accelerate the rate of wound closure in this population. This study (ClinicalTrials.gov Identifier: NCT02209051) was designed to evaluate dehydrated amniotic membrane allograft (DAMA) (AMNIOEXCEL, Derma Sciences Inc, Princeton, NJ) plus standard of care (SOC) compared to SOC alone for the closure of chronic diabetic foot ulcers (DFUs).MATERIALS AND METHODS: This prospective, open-label, randomized, parallel group trial was implemented at 8 clinical sites in the United States. Eligibility criteria included adults with type 1 or type 2 diabetes mellitus who have 1 or more ulcers with a Wagner classification of grade 1 or superficial 2 measuring between 1 cm2 and 25 cm2 in area, presenting for more than 1 month with no signs of infection/osteomyelitis; ABI > 0.7; HbA1c Less than 12%; and serum creatinine less than 3.0 mg/dL. Eligible subjects were randomized (1:1) to receive either SOC alone (n = 14) or DAMA+SOC (n = 15) until wound closure or 6 weeks, whichever occurred first. The endpoint was the proportion of subjects with complete wound closure (defined as complete reepithelialization without drainage or need for dressings). RESULTS: Thirty-five percent of subjects in the DAMA+SOC cohort achieved complete wound closure at or before week 6, compared with 0% of the SOC alone cohort (intent-to-treat population, P = 0.017). There was a more robust response noted in the per protocol population, with 45.5% of subjects in the DAMA+SOC cohort achieving complete wound closure, while 0% of SOC-alone subjects achieved complete closure (P = 0.0083). No treatment-related adverse events were reported. CONCLUSION: The results suggest DAMA is safe and effective in the management of DFUs, but additional research is needed. PMID: 26978860 [Indexed for MEDLINE]
Appears in following Topics:
Diabetic Foot Ulcer - Treatment
Cellular and/or Tissue Based Products